Migalastat Hydrochloride Purification via Segmented Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing migalastat hydrochloride result in batches with high impurity levels, which affect the drug's purity and efficacy in treating Fabry disease.
Innovation Solution
The development of methods involving the reaction of D-(+)-galactose with pivaloyl imidazole to produce 1,2,3,6-tetrapivaloyl-D-galactofuranoside, followed by specific chromatographic tests and purification steps to ensure low levels of impurities, such as Compound B, and subsequent conversion to intermediate grade migalastat hydrochloride, ultimately producing high-purity migalastat hydrochloride.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current production methods are used, then production efficiency is maintained, but impurity levels in migalastat hydrochloride batches remain high
Solution Approach 1:
The production process is divided into multiple discrete stages with specific purification operations at each step. The method segments the synthesis into: (1) reaction of D-(+)-galactose with pivaloyl imidazole to produce 1,2,3,6-tetrapivaloyl-D-galactofuranoside with controlled Compound B levels, (2) conversion to 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside, (3) reduction to migalastat, and (4) conversion to migalastat hydrochloride with final purification through crystallization from ethanol/water solvent system. Each stage includes specific purification operations to remove impurities cumulatively.
Solution Approach 2:
The method performs preliminary purification actions at early stages of synthesis. Specifically, the reaction conditions are optimized from the outset to produce 1,2,3,6-tetrapivaloyl-D-galactofuranoside with 3% area or less of Compound B, rather than allowing impurities to accumulate and then removing them later. This preliminary control of impurity formation simplifies subsequent purification steps and maintains production efficiency.
Solution Approach 3:
The method employs specific parameter changes to achieve high purity: (1) controlling reaction temperature and time parameters to minimize Compound B formation, (2) using specific solvent systems (ethanol/water) for crystallization to achieve 98.5% or greater purity, (3) optimizing pH and temperature during hydrolysis and reduction steps. These parameter optimizations enable high purity production without requiring excessive additional purification operations.
2Manufacturing precision
If additional purification steps are added, then impurity levels decrease, but process complexity increases
Solution Approach 1:
The method merges purification operations with the synthesis steps themselves rather than adding separate dedicated purification stages. For example, the crystallization step serves both as a isolation method and as the primary purification operation, achieving 98.5% or greater purity. The hydrolysis and reduction steps are combined in a sequential manner where each step's conditions are optimized to minimize impurity carryover to the next step, reducing the need for additional intermediate purification operations.
Solution Approach 2:
The synthesis process is designed so that each reaction step inherently favors the formation of the desired product with minimal impurities under optimized conditions. The reaction of D-(+)-galactose with pivaloyl imidazole self-regulates to produce 1,2,3,6-tetrapivaloyl-D-galactofuranoside with 3% area or less of Compound B when proper stoichiometry and conditions are used. This self-purifying characteristic of the optimized reactions reduces the burden on subsequent purification steps.
3Manufacturing precision
If reaction conditions are optimized for purity, then impurity levels decrease, but production time increases
Solution Approach 1:
The method employs continuous optimized reaction conditions throughout each synthesis stage rather than using multiple batch cycles with intermediate purifications. The reaction of D-(+)-galactose with pivaloyl imidazole proceeds under continuous optimized conditions to produce the intermediate with controlled impurity levels. The subsequent conversion, reduction, and crystallization steps follow in continuous sequence without interrupting for separate purification operations, maintaining production speed while achieving high purity through optimized continuous processes.
Solution Approach 2:
The method uses specific parameter optimizations that enable faster reaction rates without compromising purity. For example, the crystallization from ethanol/water solvent system achieves both high purity (98.5% or greater) and reasonable crystallization rates by optimizing temperature gradients and solvent ratios. The hydrolysis and reduction steps use optimized temperature and pH parameters that accelerate reaction rates while minimizing impurity formation, reducing overall production time without sacrificing purity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods ensure the production of migalastat hydrochloride with controlled impurity levels, enhancing its purity and effectiveness as a treatment for Fabry disease, meeting pharmaceutical grade standards.
Implementation Method 1
performing a chromatographic test on the batch to determine that the batch has 3% or less of Compound B
Implementation Method 2
performing high performance liquid chromatography (HPLC) on the batch to identify a peak associated with the Compound B, and determining that the area under the second peak is 3% or less of a total area under the identified HPLC peaks
Data Source
AI summary
Provided are methods of producing a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of determining the purity of a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of distributing a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of assessing suitability of migalastat hydrochloride for medical use.